Literature DB >> 34766230

Potential in vitro therapeutic effects of targeting SP/NK1R system in cervical cancer.

Mahtab Mozafari1, Safieh Ebrahimi2,3, Reza Assaran Darban4, Seyed Isaac Hashemy5,6.   

Abstract

BACKGROUND: Cervical cancer, an aggressive gynecological cancer, seriously threatens women's health worldwide. It is recently reported that neuropeptide substance P (SP) regulates many tumor-associated processes through neurokinin-1 receptor (NK1R). Therefore, we used cervical cancer cell line (HeLa) to investigate the functional relevance of the SP/NK1R system in cervical cancer pathogenesis.
METHODS: Cellular proliferation and cytotoxicity were analyzed by colorimetric MTT assay. Quantitative real-time PCR (qRT-PCR) was used to measure mRNA expression levels of desired genes. Cell cycle distribution and apoptosis were evaluated by flow cytometry. A wound-healing assay was employed to assess migration ability.
RESULTS: We found that the truncated isoform of NK1R(NK1R-Tr) is the dominantly expressed form of the receptor in Hela cells. We also indicated that that SP increased HeLa cell proliferation while treatment with NK1R antagonist, aprepitant, inhibited HeLa cell viability in a dose and time-dependent manner. SP also alters the levels of cell cycle regulators (up-regulation of cyclin B1 along with downregulation of p21) and apoptosis-related genes (up-regulation of Bcl-2 along with downregulation of Bax) while aprepitant reversed these effects. Aprepitant also induced arrest within the G2 phase of the cell cycle and subsequent apoptosis. Furthermore, SP promoted the migrative phenotype of HeLa cells and increased MMP-2 and MMP-9 expression while aprepitant exposure significantly reversed these effects.
CONCLUSION: Collectively, our results indicate the importance of the SP / NK1R system in promoting both proliferative and migrative phenotypes of cervical cancer cells and suggest that aprepitant may be developed as a novel treatment for combating cervical cancer.
© 2021. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  Aprepitant; Cervical cancer; Neurokinin-1 receptor; Substance P

Mesh:

Substances:

Year:  2021        PMID: 34766230     DOI: 10.1007/s11033-021-06928-3

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  41 in total

Review 1.  Tachykinins and their receptors: contributions to physiological control and the mechanisms of disease.

Authors:  Martin S Steinhoff; Bengt von Mentzer; Pierangelo Geppetti; Charalabos Pothoulakis; Nigel W Bunnett
Journal:  Physiol Rev       Date:  2014-01       Impact factor: 37.312

Review 2.  Cervical cancer worldwide.

Authors:  Mailinh Vu; Jim Yu; Olutosin A Awolude; Linus Chuang
Journal:  Curr Probl Cancer       Date:  2018-06-25       Impact factor: 3.187

Review 3.  Involvement of substance P and the NK-1 receptor in pancreatic cancer.

Authors:  Miguel Muñoz; Rafael Coveñas
Journal:  World J Gastroenterol       Date:  2014-03-07       Impact factor: 5.742

4.  Amino-acid sequence of substance P.

Authors:  M M Chang; S E Leeman; H D Niall
Journal:  Nat New Biol       Date:  1971-07-21

5.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.

Authors:  Hyuna Sung; Jacques Ferlay; Rebecca L Siegel; Mathieu Laversanne; Isabelle Soerjomataram; Ahmedin Jemal; Freddie Bray
Journal:  CA Cancer J Clin       Date:  2021-02-04       Impact factor: 508.702

Review 6.  The emerging role of substance P/neurokinin-1 receptor signaling pathways in growth and development of tumor cells.

Authors:  Hossein Javid; Fariba Mohammadi; Elnaz Zahiri; Seyed Isaac Hashemy
Journal:  J Physiol Biochem       Date:  2019-08-01       Impact factor: 4.158

Review 7.  Chemotherapy in the treatment of metastatic, persistent, and recurrent cervical cancer.

Authors:  Ramez N Eskander; Krishnansu S Tewari
Journal:  Curr Opin Obstet Gynecol       Date:  2014-08       Impact factor: 1.927

Review 8.  Biological and Pharmacological Aspects of the NK1-Receptor.

Authors:  Susana Garcia-Recio; Pedro Gascón
Journal:  Biomed Res Int       Date:  2015-09-03       Impact factor: 3.411

9.  Intensity-modulated radiotherapy combined with iodine-125 seed implantation in non-central recurrence of cervical cancer: A case report and literature review.

Authors:  Hu Feng; Yuanyuan Hu; Peng Jin; Xiangkuan Meng; Yubing Chen; Hongmei Zhang
Journal:  Oncol Lett       Date:  2017-07-26       Impact factor: 2.967

10.  Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis.

Authors:  Marc Arbyn; Elisabete Weiderpass; Laia Bruni; Silvia de Sanjosé; Mona Saraiya; Jacques Ferlay; Freddie Bray
Journal:  Lancet Glob Health       Date:  2019-12-04       Impact factor: 26.763

View more
  2 in total

Review 1.  Neurokinin-1 Receptor (NK-1R) Antagonists as a New Strategy to Overcome Cancer Resistance.

Authors:  Marilina García-Aranda; Teresa Téllez; Lauraine McKenna; Maximino Redondo
Journal:  Cancers (Basel)       Date:  2022-04-30       Impact factor: 6.575

2.  The Potential In Vitro Inhibitory Effects of Neurokinin-1 Receptor (NK-1R) Antagonist, Aprepitant, in Osteosarcoma Cell Migration and Metastasis.

Authors:  Mohammed Ali Alsaeed; Safieh Ebrahimi; Abbas Alalikhan; Seyedeh Fatemeh Hashemi; Seyed Isaac Hashemy
Journal:  Biomed Res Int       Date:  2022-09-20       Impact factor: 3.246

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.